Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

References

• WHO. The top 10 causes of death [Internet]. 2020. [cited 2021 Feb 06]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• [IARC] International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. International Agency for Research on Cancer. 2020.
   Google Scholar
• Ministry of Health. Cancer Incidence in Brazil [Internet]. Rio de Janeiro; 2017. [cited 2021 Feb 06]. Available from: https://www.inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. .
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205. .
   PubMed Web of Science ®Google Scholar
• Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019;20(3):361–370. .
   PubMed Web of Science ®Google Scholar
• Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012(4):CD006243.
   Google Scholar
• *Macedo A, Monteiro I, Andrade S, et al. Custo-efectividade de trastuzumab: no tratamento de doentes com cancro da mama em estádios iniciais em Portugal [Cost-effectiveness of trastuzumab: in the treatment of early stage breast cancer patients in Portugal]. Acta Medica Portuguesa. 2010;23(3): 475–482. Portuguese.
   PubMedGoogle Scholar
• Hall PS, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics. 2011;29(5):415–432.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33(3):411–417.
   PubMed Web of Science ®Google Scholar
• Leung W, Kvizhinadze G, Nair N, et al. Adjuvant Trastuzumab in HER2-Positive early breast cancer by age and hormone receptor status: a Cost-utility analysis. PLoS Med. 2016;13(8):e1002067.
   PubMed Web of Science ®Google Scholar
• Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant Trastuzumab therapy for early HER2-Positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36(1):91–103.
   PubMed Web of Science ®Google Scholar
• Seferina SC, Ramaekers BLT, De Boer M, et al. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the southeast Netherlands breast cancer consortium. Oncotarget. 2017;8(45):79223–79233. .
   PubMedGoogle Scholar
• Ferrusi IL, Marshall DA, Kulin NA, et al. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med. 2009;6(2):193–215.
   PubMed Web of Science ®Google Scholar
• Diaby V, Tawk R, Sanogo V, et al. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015;151(1):27–40.
   PubMed Web of Science ®Google Scholar
• Petrou P. Looking for Her (2+): a systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):115–125.
   PubMed Web of Science ®Google Scholar
• Clinical Protocols and Therapeutic Guidelines in Oncology [Internet]. Brasilia; 2018. [cited 2019 Mar 21]. Availablefrom: http://conitec.gov.br/images/Protocolos/DDT/DDT_CarcinomaMama_2018_site.pdf
   Google Scholar
• Aboutorabi A, Hadian M, Ghaderi H, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2015;7(1):98–106.
   Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007;25(5):429–442.
   PubMed Web of Science ®Google Scholar
• Estevez-Diz MDP, Testa L (Editor A). Manual of Conduct in Oncology. In: Hoff PMG, editor. 3rd ed. Sao Paulo: Publisher Atheneu; 2018. p. 276.
   Google Scholar
• Brazilian Institute of Geography and Statistics. Complete mortality tables 2017 [Internet]. Rio de Janeiro; 2017. [cited 2019 Jul 13]. Availablefrom: https://biblioteca.ibge.gov.br/visualizacao/livros/liv101628.pdf
   Google Scholar
• Welton NJ, Sutton AJ, Cooper NJ, et al. Evidence synthesis for decision making in healthcare.Chichester: Publisher Wiley; 2012. p. 293.
   Google Scholar
• Massuda A, Hone T, Leles FAG, et al. The Brazilian health system at crossroads: progress, crisis and resilience. BMJ Glob Heal. 2018;3(4):e000829.
   PubMed Web of Science ®Google Scholar
• Gobetti SW, Orair RO Progressividade tributária: a agenda negligenciada [Tax progressivity: the neglected agenda]. 2016. Portuguese.
   Google Scholar
• Gobetti SW, Orair RO. Taxation and distribution of income in Brazil: new evidence from personal income tax data. Brazilian J Polit Econ. 2017;37(2):267–286.
   Google Scholar
• Gobetti S Tributação do capital no brasil e no mundo [Taxation of capital in Brazil and worldwide]. 2018. Portuguese.
   Google Scholar
• Santos IS, Vieira FS. The right to healthcare and fiscal austerity: the Brazilian case from an international perspective. Cienc e Saude Coletiva. 2018.
   Web of Science ®Google Scholar
• Methodological guidelines: Economic evaluation guideline. [Internet]. 2a. Brasilia: ministry of health. secretariat of science, technology and strategic inputs - Department of science and technology .; 2014. 134 p.[cited 2019 Jan 13]. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf
   Google Scholar
• Briggs AH, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Rascati KL. Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins; 2009.
   Google Scholar
• Edlin R, McCabe C, Hulme C, et al. Cost effectiveness modelling for health technology assessment. Switzerland: Publisher  Springer; 2015. p. 217.
   Google Scholar
• Levine DM, Stephan D, Krehbiel T, et al. Statistics for managers using microsoft excel. USA: Pearson Educaction; 2017. p. 800.
   Google Scholar
• Walter E,organizador. Regulatory and economic aspects in oncology. Cham: Springer; 2019.
   Google Scholar
• Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• Barros AJD, Bertoldi AD. Out-of-pocket health expenditure in a population covered by the Family Health Program in Brazil. Int J Epidemiol. 2008;37(4):758–765.
   PubMed Web of Science ®Google Scholar
• Lang HC, Chen HW, Chiou TJ, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016;19(10):923–927.
   PubMed Web of Science ®Google Scholar
• Ioannou SS, Marcou Y, Kakouri E, et al. Real-world setting cost-effectiveness analysis comparing three therapeutic schemes of one-year adjuvant trastuzumab in HER2-positive early breast cancer from the Cyprus NHS payer perspective. Int J Environ Res Public Health. 2020;17(12):4339.
   Web of Science ®Google Scholar
• Genuino AJ, Chaikledkaew U, Guerrero AM, et al. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019;19(1):874.
   PubMed Web of Science ®Google Scholar
• Hajjar A, Ergun MA, Alagoz O, et al. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS One. 2019;14(6):e0217778.
   PubMed Web of Science ®Google Scholar